Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4465-4478
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4465
Table 4 Lenvatinib-related adverse events in patients with hepatocellular carcinoma, n (%)
| Event | Hepatocellular carcinoma (n = 56) | |
| Any grade | Grade 3-4 | |
| Any adverse event | 52 (92.9) | 11 (21.2) |
| Hypertension | 25 (44.6) | 2 (3.8) |
| Fatigue | 10 (17.9) | 0 |
| Decreased appetite | 13 (23.2) | 1 (1.9) |
| Diarrhea | 13 (23.2) | 2 (3.8) |
| Proteinuria | 12 (21.4) | 5 (9.6) |
| Decreased weight | 3 (5.4) | 0 |
| Hand-foot skin reaction | 6 (10.7) | 0 |
| Nausea | 5 (8.9) | 0 |
| Abdominal pain | 4 (7.1) | 0 |
| Rash | 4 (7.1) | 1 (1.9) |
| Decreased platelet count | 3 (5.4) | 0 |
| Vomiting | 1 (1.8) | 0 |
| Hypothyroidism | 2 (3.6) | 0 |
| Dysphonia | 1 (1.8) | 0 |
- Citation: Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4465